FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
Publication
, Journal Article
Jafar, TH
Published in: Lancet (London, England)
July 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet (London, England)
DOI
EISSN
1474-547X
ISSN
0140-6736
Publication Date
July 2021
Volume
398
Issue
10297
Start / End Page
283 / 284
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sodium-Glucose Transporter 2 Inhibitors
- Renal Insufficiency, Chronic
- Humans
- Glucosides
- General & Internal Medicine
- Drug Approval
- Benzhydryl Compounds
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jafar, T. H. (2021). FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England), 398(10297), 283–284. https://doi.org/10.1016/s0140-6736(21)01242-3
Jafar, Tazeen H. “FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?” Lancet (London, England) 398, no. 10297 (July 2021): 283–84. https://doi.org/10.1016/s0140-6736(21)01242-3.
Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England). 2021 Jul;398(10297):283–4.
Jafar, Tazeen H. “FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?” Lancet (London, England), vol. 398, no. 10297, July 2021, pp. 283–84. Epmc, doi:10.1016/s0140-6736(21)01242-3.
Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet (London, England). 2021 Jul;398(10297):283–284.
Published In
Lancet (London, England)
DOI
EISSN
1474-547X
ISSN
0140-6736
Publication Date
July 2021
Volume
398
Issue
10297
Start / End Page
283 / 284
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sodium-Glucose Transporter 2 Inhibitors
- Renal Insufficiency, Chronic
- Humans
- Glucosides
- General & Internal Medicine
- Drug Approval
- Benzhydryl Compounds
- 42 Health sciences